Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.

ABSTRACT:

Rationale

Keytruda (pembrolizumab) is an inhibitor of programmed cell death receptor-1 (PD-1), which was approved to treat advanced melanoma and nonsmall cell lung cancer patients who do not respond to other treatment. However, its efficacy and security in the treatment of advanced liver cancer is still under investigation.

Patient concerns

A 60-year-old man was diagnosed with pulmonary metastatic liver cancer who accepted pembrolizumab treatment after the failure of sorafenib. When injected pembrolizumab, in spite of pulmonary metastatic lesion shrink, the patient experienced severe liver dysfunction.

Diagnoses

Based on the features of the clinical signs and laboratory examination,the patient was diagnosed with pembrolizumab-induced immune-related hepatitis by exclud

SUBMITTER: Wu Z 

PROVIDER: S-EPMC5758274 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature